Caliper Life Sciences

Branford Set the Rhythm! Acquires Life Sciences Bolt-on

Retrieved on: 
Monday, November 13, 2023
Growth, Caliper Life Sciences, Research, University, Acquisition, Software, Lafayette

Lafayette ( https://lafayetteneuroscience.com/ ) is a global leader in the development and manufacturing of scientific instrumentation equipment for the life sciences, polygraph and human evaluation markets.

Key Points: 
  • Lafayette ( https://lafayetteneuroscience.com/ ) is a global leader in the development and manufacturing of scientific instrumentation equipment for the life sciences, polygraph and human evaluation markets.
  • Actimetrics is a leader in scientific instrumentation equipment and software for circadian rhythm biology and animal behavioral neuroscience, which is utilized by leading universities and research institutions globally.
  • "This acquisition provides Lafayette with the opportunity to increase its product offering to existing and new life sciences customers," said Ceon Francis, Managing Director of Branford Castle.
  • "We are excited to work with the Lafayette management team to continue to support the future growth of the company."

Adroit DI Appoints Experienced Industry Leader to drive Expansion in North America

Retrieved on: 
Tuesday, October 17, 2023
Data Management, Technology, Other Science, Networks, Research, Science, Internet, Taconic Biosciences, Organization, Carestream Health, Caliper Life Sciences, Data management, Pharmaceutical industry, Management

“I am thrilled to announce the appointment of John S. DelliSanti as President of North America and Chief Commercial Officer for Adroit DI.

Key Points: 
  • “I am thrilled to announce the appointment of John S. DelliSanti as President of North America and Chief Commercial Officer for Adroit DI.
  • His leadership has consistently delivered results by nurturing strong customer relationships and employee engagement,” said Richard Lingard, CEO Adroit DI.
  • John S. DelliSanti, President of North America and Chief Commercial Officer for Adroit DI, said, "I'm honored to join Adroit DI and lead the expansion of their innovative data management solutions across North America.
  • I look forward to partnering with Richard and the talented Adroit DI team as we help more organizations accelerate their important research."

Greenberg Traurig's Andrew (A.J.) Tibbetts to Present at MassBio Forum on AI and Machine Learning

Retrieved on: 
Thursday, September 7, 2023
Fintech, LLP, Natural language processing, Intellectual property, Research, Caliper Life Sciences, Machine learning, Drug discovery, Artificial intelligence, Roger Hawkins (drummer), Software, Medical device

BOSTON, Sept. 7, 2023 /PRNewswire-PRWeb/ -- Andrew (A.J.) Tibbetts, a shareholder at global law firm Greenberg Traurig, LLP, will present at the Massachusetts Biotechnology Council (MassBio) forum Sept. 11.

Key Points: 
  • Tibbetts, a shareholder at global law firm Greenberg Traurig, LLP, will present at the Massachusetts Biotechnology Council (MassBio) forum Sept. 11.
  • Tibbetts , a shareholder at global law firm Greenberg Traurig, LLP , will present at the Massachusetts Biotechnology Council (MassBio) forum Sept. 11.
  • Tibbetts will present " AI and Machine Learning: Parsing Hype from Real Successes in the Life Sciences ," discussing how AI and machine learning may have the potential to revolutionize drug discovery and clinical trials, as well as a lack of clinical data and its impact in life sciences.
  • Additionally, he will break down what to expect from these technologies in the coming years based on real-world successes.

Codetta Bio Appoints New Vice President of Product Management to Lead Commercial Strategy

Retrieved on: 
Tuesday, August 22, 2023
Data Management, Technology, Professional Services, Health, General Health, Health Technology, Other Science, Other Technology, Research, Data Analytics, Science, Drug discovery, Product management, Caliper Life Sciences, PerkinElmer, Multimedia, Patient, Genomics, Coda (music), Marketing, Bio, Software, Management

Codetta Bio , the life sciences company developing advanced multiomic biomarker measurement tools, announced today that Jeremy Lambert has joined the company as Vice President of Product Management.

Key Points: 
  • Codetta Bio , the life sciences company developing advanced multiomic biomarker measurement tools, announced today that Jeremy Lambert has joined the company as Vice President of Product Management.
  • In this role, Lambert will lead the development and execution of Codetta’s commercial strategy as the company brings its breakthrough multiomic solution to market.
  • View the full release here: https://www.businesswire.com/news/home/20230822205083/en/
    Jeremy Lambert, Vice President of Product Management at Codetta Bio (Graphic: Business Wire)
    “Jeremy has a proven track record as a strategic, customer and market-focused leader in life sciences technology product development,” said Anthony Lemmo, CEO of Codetta Bio.
  • “I’m looking forward to working alongside the rest of the Codetta team to develop a commercial strategy that will make our innovative solution widely accessible and ultimately improve outcomes for patients everywhere.”
    To learn more about Codetta Bio, please visit http://www.codettabio.com .

Thompson Street Capital Partner’s Vector Laboratories Acquires Quanta BioDesign

Retrieved on: 
Tuesday, July 25, 2023
Professional Services, Health, Apps, Applications, Technology, Finance, Pharmaceutical, Biotechnology, Quanta, Vector, Doctor of Philosophy, Click chemistry, Plain City, Caliper Life Sciences, Acquisition, TSCP, Drug discovery, Immunohistochemistry, Growth, Fine chemical

Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, today announced the acquisition of Quanta BioDesign , the inventor of discrete polyethylene glycol (dPEG®) technology for advanced bioconjugate and payload delivery design for life science and biopharma applications, by Vector Laboratories , a portfolio company of TSCP and the pioneer of innovative proteomic and glycomic research solutions.

Key Points: 
  • Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, today announced the acquisition of Quanta BioDesign , the inventor of discrete polyethylene glycol (dPEG®) technology for advanced bioconjugate and payload delivery design for life science and biopharma applications, by Vector Laboratories , a portfolio company of TSCP and the pioneer of innovative proteomic and glycomic research solutions.
  • This acquisition further expands Vector Laboratories’ portfolio of bioconjugation linkers and dyes and builds on its manufacturing and bioconjugation capabilities to better serve partners across biopharma and the life sciences.
  • “This acquisition supports Vector Laboratories’ long-term strategic vision of accelerating the pace of scientific discovery for life science companies and transformational treatments and approaches for biopharma companies,” said Lisa V. Sellers, PhD, CEO of Vector Laboratories.
  • Vector was the first company to commercialize avidin-biotin enzyme complex kits for immunohistochemistry and antifade mounting media for immunofluorescence.

Vector Laboratories Acquires Quanta BioDesign to Continue Growth Strategy of Strengthening Development and Manufacturing Services for Life Science and Biopharma Customers

Retrieved on: 
Monday, July 17, 2023
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Science, Clinical Trials, Quanta, Laboratory, Eye, Cancer, Doctor of Philosophy, Propylene glycol, Click chemistry, Plain City, Caliper Life Sciences, Acquisition, Drug discovery, Immunohistochemistry, Death, Pharmaceutical industry, Vector

This most recent acquisition further expands Vector Laboratories’ portfolio of bioconjugation linkers and dyes and builds on its manufacturing and bioconjugation capabilities to better serve partners across biopharma and the life sciences.

Key Points: 
  • This most recent acquisition further expands Vector Laboratories’ portfolio of bioconjugation linkers and dyes and builds on its manufacturing and bioconjugation capabilities to better serve partners across biopharma and the life sciences.
  • “This acquisition is valuable because it supports Vector Laboratories’ long-term strategic vision of accelerating the pace of scientific discovery for life science companies and transformational treatments and approaches for biopharma companies,” said Lisa V. Sellers , PhD, CEO of Vector Laboratories.
  • Quanta BioDesign was founded in 1997 by Paul D. Davis, PhD, in response to his wife’s death due to cancer.
  • Vector Laboratories was the first company to commercialize avidin-biotin enzyme complex kits for immunohistochemistry and antifade mounting media for immunofluorescence.

ARCH Venture Partners Announces Appointment of Kevin Hrusovsky as Venture Partner

Retrieved on: 
Thursday, May 25, 2023
Roman Hrusovsky, Ohio State University, New England, Professional corporation, Ohio University, CALP, Executive, Drug development, University, Framingham State University, DuPont, ARCH Venture Partners, Medicine, ARCH, PerkinElmer, PKI, Caliper Life Sciences, Health, Management

CHICAGO, May 25, 2023 /PRNewswire/ -- ARCH Venture Partners today announced the appointment of life sciences industry veteran Kevin Hrusovsky as Venture Partner.

Key Points: 
  • CHICAGO, May 25, 2023 /PRNewswire/ -- ARCH Venture Partners today announced the appointment of life sciences industry veteran Kevin Hrusovsky as Venture Partner.
  • "Kevin has been instrumental in the success of multiple ARCH portfolio companies, and we look forward to building the next generation of companies together," said ARCH Co-founder and Managing Director Keith Crandell.
  • "ARCH is committed to bringing the best entrepreneurs, experience, value-add perspective, and network to advance our portfolio companies.
  • Kevin has deep experience in the industry and is an important addition to the ARCH team."

Immutep Quarterly Activities Report

Retrieved on: 
Thursday, April 27, 2023
Amgen, Institutional review board, European Medicines Agency, G&A, Rated R, Patent, Patient, NSW, Acceleration, Disease, CSO, Lung cancer, EMA, Related party transaction, Global Medical Device Nomenclature, PD-1, Phase, FDA, Death, Safety, Health care, MHC, Cancer, NSCLC, CMO, Immunotherapy, PFS, US, IRB, Grant, Pembrolizumab, Therapy, Family, ORR, Kinetics, Infection, Doctor of Philosophy, Progression-free survival, Clinical trial, OS, Paclitaxel, ASX, B cell, Part, ELCC, Marketing, Caliper Life Sciences, IMM, MHC class II, Novartis, APC, Active immunotherapy, Breast cancer, Palladium, Pharmaceutical industry, Vaccine, Cryptocurrency, Immutep

SYDNEY, AUSTRALIA, April 27, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, provides an update on the ongoing development of its product candidates, eftilagimod alpha (efti) and IMP761 for the quarter ended 31 March 2023 (Q3 FY23).

Key Points: 
  • Subsequent to quarter end TACTI-003 has reached 75% enrolment, and Immutep expects to complete enrolment by mid-year positioning the Company to report top-line results in H2 of CY2023.
  • The net cash used in R&D activities in the quarter was A$11.52 million, compared to A$5.87 million in Q2 FY23.
  • Total net cash outflows used in operating activities in the quarter were A$14.17 million compared to A$7.02 million in Q2 FY23.
  • Immutep will continue to manage its solid cash balance carefully as it pursues its overall clinical development strategy.

Life sciences lab automation provider Automata expands into the United States

Retrieved on: 
Friday, February 24, 2023
Software, General Health, Pharmaceutical, Hardware, Robotics, Technology, Artificial Intelligence, Health Technology, Science, Biotechnology, Other Science, Health, Workflow, Genomics, Organization, Hospital, Drug discovery, Entrepreneurship, NHS, Automation, Growth, ChromeOS, Francis Crick Institute, Quality control, LINQ, Caliper Life Sciences, Fine chemical, Automaton, Series

Automata is accelerating scientific and health outcomes by making automation a reality for every lab.

Key Points: 
  • Automata is accelerating scientific and health outcomes by making automation a reality for every lab.
  • The life sciences are leading the most important scientific revolution since computing accounting for approximately 7% of all US economic activity with the global life sciences tools market alone estimated at $102B in 2021.
  • Automata enters this market at an exciting and critical time, as the US is considered the global leader in Life Sciences with more than a third of all life sciences companies headquartered in the country.
  • Automata will launch its first US office in Boston and is already supporting customers across the country with employees based in multiple states.

Intelligent Material Solutions, Inc. Received NJMEP Award for Innovator of the Year

Retrieved on: 
Friday, January 6, 2023
Nitroglycerin, The Science, Engineering & Technology Student of the Year Awards, Control, Accident, Princeton University, Transport, Kinetics, Invention, Research, Nitrous oxide, Chemical kinetics, NIST, Entrepreneurship, Research and development, Pedestrian, National Institute of Standards and Technology, STEM, Caliper Life Sciences, IMS, Material, ARPA, Television, Defense

The New Jersey Manufacturing Extension Program (NJMEP) is a non-for-profit organization backed by the National Institute of Standards and Technology (NIST) ( NJMEP ).

Key Points: 
  • The New Jersey Manufacturing Extension Program (NJMEP) is a non-for-profit organization backed by the National Institute of Standards and Technology (NIST) ( NJMEP ).
  • The innovator of the Year Award celebrates a person or organization whose innovation betters the manufacturing community in NJ, beneficially impacts STEM fields, and improves business.
  • "Intelligent Material is honored to receive this award," said Howard Bell, President and Co-Founder of IMS, "We want to thank the NJMEP staff for recognizing our unique and innovative technology."
  • IMS is a material science and technology company that develops custom rare-earth crystals as well as accompanying or stand-alone sensors.